IDLDX.ST STO
IDL Diagnostics AB (publ)
1W: -4.6%
1M: -8.0%
3M: -7.5%
YTD: +5.1%
1Y: -21.3%
kr 0.37 ($0.04)
+0.01 (+2.49%)
Weekly Expected Move ±6.6%
kr 0
kr 0
kr 0
kr 0
kr 0
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Smart Money Score
No convergence signal
Key Statistics
Market Capkr 85.2M ($8.5M)
52W Range0.25-0.53
Volume5,719
Avg Volume143,140
Beta0.94
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOGustav Sten
Employees25
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2025-05-19
Websiteidldiagnostics.com
KarlsbodavAegen 39
Stockholm 168 67
SE
Stockholm 168 67
SE
46 87 99 67 50
About IDL Diagnostics AB (publ)
Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops and markets diagnostic tests aimed at detecting cancer and bacterial infections within the Swedish market. Its product portfolio includes UBC Rapid, a point-of-care solution for both diagnosing and tracking bladder cancer; AroCell TK 210 ELISA, utilized as a biomarker for identifying tumor cells; and TUBEX TF, an in vitro diagnostic tool for pinpointing acute typhoid fever. Formerly operating as AroCell AB (publ), the company is scheduled to adopt the name IDL Diagnostics AB (publ) in May 2025. Established in 2000, its operations are headquartered in Stockholm, Sweden.
Latest News
No recent news
Recent Insider Trades
No insider trades found